Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention

Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention (PROSe-ICD)

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The overall hypothesis of this study is that subtle interactions between structural (substrate) and functional (trigger) abnormalities of the heart, some of which are genetically-determined, can be used to identify patients at high risk of sudden cardiac death (SCD). Such information may be used to better define patients most likely to benefit from replacement of an internal defibrillator (ICD). The prospective, observational study to enroll, categorize and follow patients who receive an ICD pulse generator replacement for primary prevention of SCD (PROSe-ICD) was established to : 1. to gain a better understanding of the biological mechanisms that predispose to SCD 2. to develop readily determined clinical, electrocardiographic, genetic and blood protein markers identify patients with an increased risk of dying suddenly

Who May Be Eligible (Plain English)

Who May Qualify: - History of acute MI at least 4 weeks old - Non-ischemic LV dysfunction for at least 9 months - Who have an ejection fraction (EF) \< or = to 35% - Undergone elective replacement indicator (ERI) generator replacement of an FDA-approved ICD for primary prevention of SCD within 24 months of enrollment. - Who have primary prevention implants. Who Should NOT Join This Trial: - ICD generator replacement for secondary prevention - Inability or unwillingness to provide valid willing to sign a consent form - New York Heart Association Class IV heart failure - Patients with pre-existing Class 1 indications for pacemaker therapy. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * History of acute MI at least 4 weeks old * Non-ischemic LV dysfunction for at least 9 months * Who have an ejection fraction (EF) \< or = to 35% * Undergone elective replacement indicator (ERI) generator replacement of an FDA-approved ICD for primary prevention of SCD within 24 months of enrollment. * Who have primary prevention implants. Exclusion Criteria: * ICD generator replacement for secondary prevention * Inability or unwillingness to provide valid informed consent * New York Heart Association Class IV heart failure * Patients with pre-existing Class 1 indications for pacemaker therapy.

Locations (4)

Washington Hospital Center
Washington D.C., District of Columbia, United States
University of Maryland Medical Center
Baltimore, Maryland, United States
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
Virginia Commonwealth University School of Medicine
Richmond, Virginia, United States